Wu Tongzhi, Rayner Christopher K, Horowitz Michael
Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia.
Centre of Research Excellence in Translating Nutritional Science into Good Health, The University of Adelaide, Adelaide, Australia.
Handb Exp Pharmacol. 2016;233:137-71. doi: 10.1007/164_2015_9.
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the known incretin hormones in humans, released predominantly from the enteroendocrine K and L cells within the gut. Their secretion is regulated by a complex of integrated mechanisms involving direct contact for the activation of different chemo-sensors on the brush boarder of K and L cells and several indirect neuro-immuno-hormonal loops. The biological actions of GIP and GLP-1 are fundamental determinants of islet function and blood glucose homeostasis in health and type 2 diabetes. Moreover, there is increasing recognition that GIP and GLP-1 also exert pleiotropic extra-glycaemic actions, which may represent therapeutic targets for human diseases. In this review, we summarise current knowledge of the biology of incretin hormones in health and metabolic disorders and highlight the therapeutic potential of incretin hormones in metabolic regulation.
葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽-1(GLP-1)是已知的人体肠促胰岛素激素,主要从肠道内的肠内分泌K细胞和L细胞释放。它们的分泌受多种综合机制调节,这些机制包括通过直接接触激活K细胞和L细胞刷状缘上的不同化学传感器以及一些间接的神经免疫激素环路。GIP和GLP-1的生物学作用是健康状态及2型糖尿病中胰岛功能和血糖稳态的基本决定因素。此外,人们越来越认识到GIP和GLP-1还发挥多效性的血糖外作用,这可能代表人类疾病的治疗靶点。在本综述中,我们总结了当前关于健康和代谢紊乱中肠促胰岛素激素生物学的知识,并强调了肠促胰岛素激素在代谢调节中的治疗潜力。